Brown Capital Management’s Small Company Fund includes Krystal Biotech amid 138.74% 52-week gain and $10.03 billion market cap.
Krystal Biotech (NASDAQ:KRYS) was added to the Brown Capital Management Small Company Fund during Q1 2026, reflecting confidence in its gene therapy pipeline. The stock closed at $340.21 on June 23, 2026, with a 10.95% one-month return and a 138.74% gain over the past year.
The company, a commercial-stage biotech firm, specializes in genetic medicines for diseases with unmet needs, using a proprietary virus-based delivery system for repeat dosing. Its market capitalization stands at $10.03 billion, underscoring its growth trajectory in the sector.
The fund’s move highlights Krystal Biotech’s resilient revenue stream and potential in localized gene therapy treatments, aligning with broader investor interest in innovative biotech solutions.